Incyte Corp
NASDAQ: INCY
$65.65
-$1.17 (-1.7%)
Real Time Data Delayed 15 Min.
INCY Articles
These are the top analyst upgrades and downgrades featured by 24/7 Wall St. for Friday, October 31, 2014.
Published:
Incyte has serious upside potential, but the inherent risk within it may be too much for some investors to bear.
Published:
These are the top analyst upgrades, downgrades and initiations covered by 24/7 Wall St. for Wednesday, September 17, 2014.
Published:
SunTrust Robinson Humphrey opens up coverage of the biotech sector with four top biotech stocks to buy and one Neutral-rated stock.
Published:
In a new research report, UBS analysts are very positive on some top biotech stocks before second-quarter earnings numbers hit the tape.
Published:
A new research report from Cowen cautions that progress on a cure for pancreatic cancer is slow, but steady. Drugs from three companies though have been favorably viewed by consultants.
Published:
ThinkstockThe conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance at the American Society of Clinical Oncology yearly conference. Many of...
Published:
Here are the top analyst upgrades, downgrades and initiations seen from Wall Street on Tuesday, April 29, 2014. They include Buffalo Wild Wings, Coca-Cola, DSW and Intuitive Surgical.
Published:
In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are making major advances in cancer therapeutics. Here is the UBS list of stocks that are rated...
Published:
In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off that may provide investors some incredible outsized gains over the rest of the year.
Published:
New drug innovations are affecting the way that physicians treat such debilitating and deadly diseases as cancer. In a new research report, Jefferies presents the top drug innovations that investors...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday, February 26, 1014. The include LinkedIn, Safeway, NII Holdings, Rangold Resources and...
Published:
24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January.
Published:
Before the markets opened Wednesday morning, drug giant Merck & Co. reported fourth-quarter and full-year 2013 results that failed to dazzle. But shares traded higher in the premarket session.
Published:
Last Updated:
Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across the board. Investors who...
Published: